Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
neoMONARCH trial: what clinicians have said so far
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- NCT02441946 ↗
- Completed
- Eli Lilly and Company
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on neoMONARCH (abemaciclib plus anastrozole; abemaciclib in postmenopausal HR+/HER2- early-stage breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on neoMONARCH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 YouTube videos | |
| 5 posts on X | |
| 2 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma
- Interventions
- Abemaciclib; Loperamide; Anastrozole
- Arms
- Abemaciclib + Anastrozole · Experimental
- Abemaciclib · Experimental
- Anastrozole · Active comparator
- Enrollment
- 224
- Primary outcomes
- Percent Change From Baseline to 2 Weeks in Ki67 Expression
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2015
- Primary completion
- Aug 16, 2016
- Results posted
- Yes
- Registry record
- NCT02441946 · updated Jun 17, 2020
Publications
linked from the registry- Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. 2022 Apr;192(2):457-462. doi: 10.1007/s10549-022-06525-3. Epub 2022 Jan 25. PubMed 35076812
- Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15. PubMed 31615937